MedPath

Palforzia: A New Hope for Children with Peanut Allergy

Palforzia, a treatment for peanut allergy in children aged 1 to 17, has shown promising results in clinical trials, enabling some patients to tolerate small amounts of peanut protein with only mild symptoms. The treatment involves a phased approach under medical supervision and requires a prescription. Despite potential side effects, the European Medicines Agency has concluded that the benefits of Palforzia outweigh its risks.

Palforzia is a groundbreaking treatment for children aged 1 to 17 suffering from peanut allergy, available in powder form within capsules or sachets. Patients mix the powder with soft food for consumption. The treatment is divided into three phases: an initial clinic-based phase with increasing doses under medical observation, followed by a home-based phase with daily doses increasing every two weeks, and finally, a maintenance phase with a daily dose to sustain the medicine's effects.
Clinical trials involving over 800 children have demonstrated Palforzia's efficacy. Notably, 50% of children aged 4 to 17 and 68% of those aged 1 to 3 could tolerate 1,000 mg of peanut protein with only mild symptoms, a significant improvement over placebo groups. However, Palforzia is not without its side effects, including urticaria, cough, erythema, and abdominal pain among others. It is contraindicated in patients with severe asthma, swallowing difficulties, or recent severe allergic reactions.
The European Medicines Agency has endorsed Palforzia, recognizing its benefits surpass the risks. Patients and caregivers are provided with comprehensive information on managing the treatment and its risks, including a patient card to carry at all times. Continuous monitoring of Palforzia's use and side effects ensures patient safety remains a priority.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Palforzia Receives European Commission Approval for Peanut Allergy Treatment in Toddlers

The European Commission has approved Palforzia for treating peanut allergies in toddlers aged 1-3, expanding its availability in Europe.
This approval follows the FDA's decision in July 2024, making Palforzia the only oral immunotherapy approved for this age group in both regions.

EMA Validates Application for Less Frequent Elfabrio Dosing in Fabry Disease

The EMA has validated an application for a less frequent Elfabrio (pegunigalsidase alfa) regimen for Fabry disease, potentially reducing treatment burden.
The proposed regimen involves administering Elfabrio every four weeks at 2 mg/kg, compared to the current bi-weekly regimen of 1 mg/kg.

Palforzia Receives Positive CHMP Opinion for Peanut Allergy Treatment in Toddlers

The European Medicines Agency's CHMP has recommended Palforzia for treating peanut allergies in toddlers aged 1-3, marking a potential expansion of its use.
Palforzia, developed by Stallergenes Greer, aims to desensitize individuals to peanut allergens through controlled oral immunotherapy.

Omalizumab (Xolair) Receives FDA Approval for Food Allergies in Young Children

The FDA has approved omalizumab (Xolair) for treating severe food allergies in children as young as one year old, offering new hope for millions.
Omalizumab, initially developed for asthma, works by binding to allergy cells and removing them from circulation, reducing the risk of anaphylaxis.

Fasenra Approved in EU for Eosinophilic Granulomatosis with Polyangiitis

The European Commission has approved Fasenra (benralizumab) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
In the MANDARA phase 3 clinical trial, nearly 60% of patients treated with Fasenra achieved remission, comparable to mepolizumab, with 41% able to taper off oral corticosteroids.

Fasenra Approved in the EU for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca's Fasenra (benralizumab) has been approved in the EU for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
The approval was based on the Phase III MANDARA trial, which demonstrated comparable remission rates between Fasenra and mepolizumab.

Apremilast Approved for Pediatric Psoriasis and Focus on Skin of Color Disparities

Apremilast (Otezla) has been approved in the US for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis, offering a new oral treatment option.
The FDA approval marks apremilast as the first oral medication available for young patients with severe plaque psoriasis, provided they weigh at least 20 kg and are candidates for phototherapy or systemic therapy.

Lurie Children's Advances Peanut Allergy Immunotherapy with Novel Approaches

Lurie Children's Hospital is conducting clinical trials for peanut allergies, focusing on reducing the risk of severe reactions from accidental exposure.
A Phase 3 trial is underway, evaluating a peanut protein skin patch (Viaskin) for children aged 4-7, aiming for improved tolerability over oral immunotherapy.

Prota Therapeutics' Peanut Allergy Therapy Shows Lasting Remission Benefits

Prota Therapeutics' PRT120 and PRT100 peanut oral immunotherapies demonstrate sustained benefits two years post-treatment, including improved quality of life.
A study showed participants achieving remission experienced fewer allergic reactions and no moderate or severe reactions, or need for epinephrine.

FDA Expands Palforzia Approval to Include Children Aged 1-3 with Peanut Allergy

The FDA has expanded the approval of Palforzia to include children aged 1 through 3 years with a confirmed peanut allergy.
Palforzia is designed to mitigate allergic reactions, including anaphylaxis, that may occur due to accidental peanut exposure.

Reference News

[1]
Palforzia | European Medicines Agency (EMA)
ema.europa.eu · Dec 21, 2020

Palforzia, a peanut allergy treatment, is administered in phases, starting with supervised doses in a clinic, followed b...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy